Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kevin J. Curran"'
Autor:
Heather, Stefanski, Anne, Eaton, Christina, Baggott, Jenna, Rossoff, Michael R, Verneris, Amy K, Keating, Snehit, Prabhu, Holly L, Pacenta, Christine L, Phillips, Julie-An, Talano, Amy, Moskop, Steven P, Margossian, Gary Doug, Myers, Nicole A, Karras, Patrick A, Brown, Muna, Qayed, Michelle L, Hermiston, Prakash, Satwani, Christa, Krupski, Rachel, Wilcox, Cara A, Rabik, Vanessa A, Fabrizio, Vasant, Chinnabhandar, A Yasemin, Goksenin, Emily, Egeler, Sharon, Mavroukakis, Kevin J, Curran, Crystal L, Mackall, Theodore W, Laetsch, Liora M, Schultz
Publikováno v:
Blood advances, vol 7, iss 4
Remarkable complete response rates have been shown with tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy targeting CD19, in patients up to age 26 years with refractory/relapsed B-cell acute lymphoblastic leukemia; it is US Food and
Autor:
Audrey Mauguen, Snehit Prabhu, Christine L Phillips, Kevin J. Curran, Michael Kunicki, Prakash Satwani, Theodore W. Laetsch, Rachel Wilcox, Muna Qayed, Vasant Chinnabhandar, Crystal L. Mackall, Steven P. Margossian, Michael R. Verneris, Michelle L. Hermiston, Vanessa A Fabrizio, Christina Baggott, Julie-An An Talano, Emily Egeler, Gary Doug Myers, A. Yasemin Goksenin, Amy Moskop, Cara A Rabik, Holly L Pacenta, Amy K. Keating, Jenna Rossoff, Christa Krupski, Heather E. Stefanski, Patrick A. Brown, Nicole Karras, Jaap Jan Boelens, Sharon Mavroukakis, Liora M. Schultz
Publikováno v:
Blood advances, vol 6, iss 7
Chimeric antigen receptor (CAR) T cells provide a therapeutic option in hematologic malignancies. However, treatment failure after initial response approaches 50%. In allogeneic hematopoietic cell transplantation, optimal fludarabine exposure improve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fab5a5590ca98bdc6c2ccd6b052b9feb
https://escholarship.org/uc/item/6xt142fk
https://escholarship.org/uc/item/6xt142fk
Autor:
Heather E. Stefanski, Liora M. Schultz, Yasemin Goksenin, Michelle L. Hermiston, Vanessa A Fabrizio, Christina Baggott, Nicole Karras, M. Christa Krupski, Vasant Chinnabhandar, Steven P. Margossian, Holly L Pacenta, Christine L Phillips, Douglas Myers, Kevin J. Curran, Lauren Pommert, Rachel Wilcox, Patrick A. Brown, Muna Qayed, Amy K. Keating, Amy Moskop, Erin H. Breese, Michael R. Verneris, Jenna Rossoff, Cara A Rabik, Crystal L. Mackall, Theodore W. Laetsch, Prakash Satwani, Snehit Prabhu, Julie-An Talano, Erin M. Guest
Publikováno v:
Blood advances, vol 6, iss 14
Infants with B-cell acute lymphoblastic leukemia (B-ALL) have poor outcomes because of chemotherapy resistance leading to high relapse rates. Tisagenlecleucel, a CD19-directed chimeric antigen receptor T-cell (CART) therapy, is US Food and Drug Admin
Autor:
Andromachi Scaradavou, Meghan A. Higman, Barbara Spitzer, Jennifer Allen, Nicholas D. Yeager, Audrey Mauguen, Nancy A. Kernan, Elliot Stieglitz, Maria Cancio, Farid Boulad, Niketa C. Shah, Kevin J Curran, Vanessa A Fabrizio, Susan E. Prockop, Steven P. Margossian, Richard J. O'Reilly, Renier J. Brentjens, Jaap Jan Boelens
Publikováno v:
Bone marrow transplantation, vol 55, iss 11
Bone marrow transplantation
Bone marrow transplantation
To define the tolerability and outcome of allogeneic hematopoietic stem cell transplant (allo-HSCT) following CAR T-cell therapy, we retrospectively reviewed pediatric/young adult patients with relapsed/refractory B-ALL who underwent this treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32cde197e69454cd2acee0da2cb995dc
https://escholarship.org/uc/item/9sv0d1wj
https://escholarship.org/uc/item/9sv0d1wj